Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

DBVT vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAMP Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–2 Matrix Metrics)

CAMP Overall Winner 6-Pillar Tally: DBVT 1 – 4 CAMP (1 Tie) Matrix Metrics: DBVT 2 – 5 CAMP

As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DBVT carries a Unified Composite Score of 29.7/100 (SELL) at $9.96 (N/M Forward P/E, -5577.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin).

  • Technical & Structure Timing Caution: DBVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 45.0); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DBVT vs CAMP
DBVT NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$9.96
-3.02% 1D
Market Cap $692.2M
TTM Revenue $3.7M
Forward P/E N/M
Beta / 30D Vol 1.18β · 76% Vol
Unified Composite Score
29.7 / 100 SELL
Tech 15.0 Fund 36.0 Flow 60.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.4%), weak momentum, RSI 45
RSI-14: 45.0 · SMA20: $10.30 · SMA50: $10.71
CAMP NASDAQ Head-to-Head Winner
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (DBVT 1 – 4 CAMP)

Columns: Metric · DBVT · CAMP
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 142.9x 26.6x
2. Growth & Scale CAMP
Revenue Growth (YoY) -42.9% +138.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.7M $5.3M
Market Cap $692.2M $238.5M
3. Profitability & Quality CAMP
Gross Margin 100.0% N/A
Operating Margin -5577.0% -991.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -205.8% -146.1%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$192M -$26M
Cash Flow Margin N/A N/A
Net Cash / Leverage $158M Net Cash $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DBVT
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 64.5% (13th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DBVT (2) vs CAMP (5)
Institutional Metric DBVT CAMP Criterion Row Edge
Market Capitalization
Scale
$692.2M $238.5M Larger Scale DBVT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-42.9% +138.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-5577.0% -991.8% Higher Margin CAMP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-205.8% -146.1% Higher ROE CAMP
52-Week Range Position
Momentum
8% ($9–$26) 22% ($3–$8) Stronger Trend CAMP
Beta / 30D Volatility
Risk Regime
1.18β · 76% Vol 1.34β · 94% Vol Lower Realized Risk DBVT
Unified Institutional Score
Composite Signal
29.7 / 100 (SELL) 43.9 / 100 (HOLD) Higher Composite CAMP
Trailing 12M Revenue (USD)
Operating Scale
$3.7M $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 142.9x EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$192M ($158M Net Cash) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +14.76 pp
DBVT: +11.04% · CAMP: +25.8%
3M Horizon CAMP +17.56 pp
DBVT: -32.61% · CAMP: -15.05%
6M Horizon CAMP +41.37 pp
DBVT: -46.19% · CAMP: -4.82%
1Y Horizon CAMP +21.11 pp
DBVT: -24.77% · CAMP: -3.66%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DBVT Revenue CAMP Revenue DBVT Op. Margin CAMP Op. Margin Margin Leader
FY2019 $10M N/A -1162.8% N/A DBVT
FY2020 $10M N/A -1408.7% N/A DBVT
FY2021 $10M N/A -1727.6% N/A DBVT
FY2022 $0M N/A -1994.9% N/A DBVT
FY2023 $20M $0M -486.0% -14822.6% DBVT
FY2024 $0M $0M -2808.7% -8142.3% DBVT
FY2025 $10M $0M -2609.2% -1502.4% CAMP

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DBVT SURGE
5d in phase · OBV ACCUMULATION
Current IV 64.5%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DBVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DBVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.2M market capitalization and -5577.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DBVT vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DBVT carries a Unified Composite Score of 29.7/100 (SELL) at $9.96 (N/M Forward P/E, -5577.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin). Technical & Structure Timing Caution: DBVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 45.0); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAMP leads the Growth & Scale pillar: DBVT posts -42.9% YoY revenue growth and +0.0% YoY earnings growth on $3.7M TTM revenue (100.0% gross margin, -5577.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), DBVT cumulative revenue shifted +0.0% while CAMP shifted N/A. In operating R&D and SG&A reinvestment, DBVT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

CAMP screens cheaper on headline valuation multiples. DBVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 142.9x EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DBVT (-205.8% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, DBVT carries 64.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.18β · 76% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.